Marines (ES)
{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~28 mi. (Valencia, Spain, +89 more cities)
facility
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1332)
biomarker
ER Positive, +2 more biomarkers
condition
Breast Carcinoma
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~28 mi. (Valencia, Spain, +226 more cities)
facility
Instituto Valenciano de Oncologia ( Site 0331)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~28 mi. (Valencia, Spain, +140 more cities)
facility
Hospital General Universitario de Valencia ( Site 0595)
condition
Hepatocellular Carcinoma
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~28 mi. (Valencia, Spain, +207 more cities)
facility
Hospital Clinico Universitario de Valencia ( Site 1355)
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~28 mi. (Valencia, Spain, +159 more cities)
facility
Instituto Valenciano de Oncologia - IVO ( Site 0662)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~28 mi. (Valencia, Spain, +163 more cities)
facility
Instituto Valenciano de Oncologia - IVO ( Site 0679)
condition
Bladder Urothelial Carcinoma
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
~28 mi. (Valencia, Spain, +92 more cities)
facility
Hospital La Fe de Valencia ( Site 0105)
condition
Bladder Urothelial Carcinoma
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
city
~28 mi. (Valencia, Spain, +109 more cities)
facility
Hospital General Universitario de Valencia
biomarker
KRAS G12C
condition
Colorectal Carcinoma, +2 more conditions
drug
anti-PD-1 antibody, +3 more drugs
drug type
immunotherapy, +2 more types
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~28 mi. (Valencia, Spain, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
condition
Breast Carcinoma
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type